Milestones
2013
PRESENT
-
2013 .12
Hunilife Biotechnology., Lnc. was formally established, focusing on the development of new drugs. The drugs developed include antibodies, cytokines, and new drug delivery system chemicals for the treatment of cancer, immune disorders and other diseases.
-
2015 .10
Signed a development licensing agreement for anti-ENO1 monoclonal antibody drugs with the Development Center for Biotechnology and the National Health Research Institutes; it exclusively authorizes the right to develop and apply global drugs for immune-related diseases and cancers.
-
2016 .12
Signed an agreement with Japan's Shimadzu to introduce its Lactosome nanoparticle drug delivery technology to jointly develop new cancer treatment drugs.
-
2017 .08
We applied for the anti-ENO1 monoclonal antibody drug HuL001 and were approved by the Ministry of Economic Affairs as a new biotechnology company.
-
2018 .01
The A+ Enterprise Innovation R&D Quenching Plan of the Technology Department of the Ministry of Economic Affairs was reviewed and approved.
-
2019 .06
Study May Proceed letter。Confirm with the US FDA that through the IND application, you can enter the first phase of human clinical trials, and send a Study May Proceed letter.
-
2021 .6
The TFDA IND application was approved and the first phase of human clinical trials began.
-
2021 .07
The A+ rapid review clinical trial plan of the Technology Department of the Ministry of Economic Affairs was reviewed and approved.
-
2022 .03
Completed the first phase clinical trial on healthy subjects at Tamsui Mackay Hospital with good safety